Will China's Enlarged Medical Insurance System Cover More Oncology Treatments?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Although China's pharmaceutical market slowed down in the first quarter of 2011 due to price cuts and policy headwinds, it still grew at 14.5% compared to the same period last year, according to data from investment brokerage Citi. Growth largely was driven by increasing medical expenses in the world second largest economy, and in particular was fueled by China's second and third-tier cities, away from the coast, which saw first quarter prescription drug growth rates between 20-30% year over year
You may also be interested in...
Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.
Lost In Reimbursement? Innovative Drugs Encounter Lengthy Delays In China – IMS Study
A market access study conducted by IMS and RDPAC sheds lights on regulatory and reimbursement challenges facing MNCs in China.
China’s Healthcare Reform Needs Resource Allocation Shift – Healthcare Officials
Fundamental shift in resource allocation, physician incentive systems and reforms to public hospitals critical say key healthcare officials.